Print Page  Close Window

Investor Relations
Corporate Profile

We are Zogenix.

Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.

A significant number of migraine and chronic pain patients are not being effectively treated, despite the availability of current therapies. These patients deserve access to safe and effective treatments. Zogenix is committed to ensuring the safe and approp... More >>

Latest PresentationsMore >>
Download Documentation Zogenix June 2014 Investor Presentation
Get help downloading or viewing the above file types
Stock Quote
ZGNX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.03 (2.03%)
Data as of 07/30/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
07/22/14Zogenix Announces Conference Call and Webcast to Present Second Quarter 2014 Financial Results
Conference Call Scheduled for August 5, 2014 at 4:30 pm ET SAN DIEGO, July 22, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the second quarter ended June 30, 2014, after the market closes on Tuesday, August 5, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), t... 
Printer Friendly Version
07/17/14Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board
Board Commends Comprehensive Surveillance Program, Educational Efforts for Zohydro(R) ER SAN DIEGO, July 17, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that David Brushwood, J.D., R.Ph., recently-retired Professor Emeritus of Pharmaceutical Outcomes and Policy at the University of Florida, College of Pharmacy, has joined t... 
Printer Friendly Version
07/14/14Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System
Covers Fundamental Delivery Profile Needed to Achieve Reliable Subcutaneous Jet Injection SAN DIEGO, July 14, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the issuance of a new patent, US 8,734,384, from the United States Patent and Trademark Office (USPTO). The patent covers the biphasic pressure profile utilized by the company's proprietary DosePro® Needle-free Delivery System. The specific pressure profile covered is essential for reliable subcutaneous injection by ne... 
Printer Friendly Version
07/09/14Zogenix Reports Positive Development on U.S. District Court Ruling
Judge Upholds Prior Decision That State Regulations Cannot Usurp Federal Law SAN DIEGO, July 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today commented on the order issued by the U.S. District Court in Massachusetts upholding its prior decision that imposing regulations to restrict access to Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, violates Constitutional law.   "This ruling upholds the important principle that a state cannot take action that could r... 
Printer Friendly Version
Upcoming EventsMore >>
08/05/14 4:30 p.m. ET
Q2 2014 Zogenix, Inc. Earnings Conference Call

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.